Molecular mechanism and potential target indication of TAK-931, a novel CDC7-selective inhibitor

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Replication stress (RS) is a recognized hallmark of cancer.
• Existing chemotherapeutics targeting RS are vital in cancer treatment.
• Cell division cycle 7 (CDC7) is an emerging target for novel RS-inducing anticancer drugs.

Purpose of the Study:

• To develop and characterize TAK-931, an oral CDC7-selective inhibitor, as a potential anticancer therapeutic.
• To elucidate the molecular mechanisms underlying TAK-931's anticancer activity.
• To identify potential cancer indications for TAK-931.

Main Methods:

• TAK-931 administration to cancer cell lines and preclinical animal models.
• Assessment of S phase delay, replication stress induction, and mitotic aberrations.
• Evaluation of antiproliferative effects and efficacy in RAS-mutant versus RAS-wild-type cancer models.
• Analysis of large-scale cell panel data for efficacy spectrum comparison.

Main Results:

• TAK-931 effectively induced S phase delay and replication stress.
• TAK-931-induced RS led to mitotic aberrations, including centrosome dysregulation and chromosome missegregation.
• Significant irreversible antiproliferative effects were observed in cancer cells and preclinical models.
• TAK-931 demonstrated enhanced antiproliferative activity in RAS-mutant cancers, confirmed in patient-derived xenografts.
• Comparative analysis revealed a unique efficacy spectrum for TAK-931.

Conclusions:

• TAK-931 is a promising oral CDC7 inhibitor with potent anticancer activity.
• The drug induces replication stress, leading to mitotic catastrophe and cell death.
• TAK-931 shows particular efficacy in RAS-mutant cancers, suggesting a targeted therapeutic strategy.
• Findings support TAK-931's potential as a next-generation anticancer drug with a distinct efficacy profile.